YUKIO AGO

Last Updated :2024/05/15

Affiliations, Positions
Graduate School of Biomedical and Health Sciences(Dentistry & Oral Health Sciences), Professor
E-mail
yukioagohiroshima-u.ac.jp
Self-introduction
We are working to elucidate the molecular mechanisms and neural circuits underlying complex brain function, mental illness, and pharmacotherapy. To understand CNS diseases caused by gene-environment interactions, we are conducting research using experimental models from cells to animals.

Basic Information

Major Professional Backgrounds

  • 2020/03/01, Hiroshima University, Graduate School of Biomedical and Health Sciences, Professor
  • 2018/06/01, 2020/02/29, Osaka University, Global Center for Medical Engineering and Informatics, Associate Professor (Concurrent post)
  • 2018/05/15, 2020/02/29, Osaka University, Laboratory of Innovative Food Science, Associate Professor (Concurrent post)
  • 2018/04/01, 2020/02/29, Osaka University, Graduate School of Dentistry, Associate Professor (Concurrent post)
  • 2018/04/01, 2020/02/29, Osaka University, Graduate School of Pharmaceutical Sciences, Associate Professor
  • 2007/04/01, 2018/03/31, Osaka University, Graduate School of Pharmaceutical Sciences, Assistant Professor
  • 2017/04/01, 2018/03/31, Osaka University, Graduate School of Dentistry, Assistant Professor (Concurrent post)
  • 2013/07/17, 2015/06/30, University of California, Los Angeles, David Geffen School of Medicine, Visiting Scholar
  • 2010/09/01, 2013/03/31, RIKEN, Center for Molecular Imaging Science, Visiting Researcher
  • 2005/04/01, 2007/03/31, Osaka University, Graduate School of Pharmaceutical Sciences, Research Associate

Educational Backgrounds

  • Osaka University, Graduate School of Pharmaceutical Sciences, Doctoral Course, Applied Biopharmaceutical Sciences, Japan, 2003/04, 2005/03
  • Osaka University, Graduate School of Pharmaceutical Sciences, Master's Course, Applied Biopharmaceutical Sciences, Japan, 2001/04, 2003/03
  • Osaka University, Faculty of Pharmaceutical Sciences, Japan, 1997/04, 2001/03

Academic Degrees

  • Ph.D., Osaka University
  • M.S., Osaka University

In Charge of Primary Major Programs

  • Dentistry
  • Oral Health Science
  • Oral Engineering

Research Fields

  • Medicine,dentistry, and pharmacy;Basic medicine;General pharmacology
  • Medicine,dentistry, and pharmacy;Pharmacy;Pharmacology in pharmacy
  • Medicine,dentistry, and pharmacy;Boundary medicine;Applied pharmacology
  • Biological Sciences;Neuroscience;Neurochemistry / Neuropharmacology
  • Biology;Basic biology;Animal physiology / Animal behavior

Research Keywords

  • Psychiatric Disorders / Developmental Disorders / Brain Function / Gene-Environment Interactions / Animal Models / Pharmacotherapy

Affiliated Academic Societies

  • The Japanese Pharmacological Society
    Related URL
  • The Japanese Society of Neuropsychopharmacology
    Related URL
  • The Japanese Society for Neurochemistry
    Related URL
  • The Japan Neuroscience Society
    Related URL
  • The Pharmaceutical Society of Japan
    Related URL
  • The Japan Society of Drug Delivery System
  • Japanese Association for Oral Biology
    Related URL
  • Japanese Society for Disability and Oral Health
    Related URL
  • The Japanese Dental Society of Anesthesiology
    Related URL
  • The Hiroshima University Dental Society
  • Society for Senescence-Accelerated Mouse (SAM) Research
    Related URL
  • Japan Transporter Research Association
  • Society for Neuroscience (SfN)
    Related URL
  • Collegium Internationale Neuro-Psychopharmacologicum (CINP)
    Related URL
  • American Society for Neurochemistry (ASN)
    Related URL

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, 4Term, Life Science
  2. 2024, Undergraduate Education, 3Term, Dental Pharmacology I
  3. 2024, Undergraduate Education, 4Term, Dental Pharmacology II
  4. 2024, Undergraduate Education, 1Term, Practice of Pharmacology
  5. 2024, Undergraduate Education, 1Term, Topics in Dental Research I
  6. 2024, Undergraduate Education, First Semester, Dental Research Practices I
  7. 2024, Undergraduate Education, Second Semester, Dental Research Practices II
  8. 2024, Undergraduate Education, 2Term, Basic and clinical integrated theory
  9. 2024, Undergraduate Education, First Semester, Dental Research Practices III
  10. 2024, Undergraduate Education, First Semester, Dental Research Practices IV （Cellular and Molecular Pharmacology）
  11. 2024, Undergraduate Education, 2Term, Pharmacology and Dental Pharmacology
  12. 2024, Undergraduate Education, Second Semester, Practice on Basic Dental Sciences
  13. 2024, Undergraduate Education, 2Term, Pharmacology and Dental Pharmacology
  14. 2024, Graduate Education (Master's Program) , First Semester, Seminar
  15. 2024, Graduate Education (Master's Program) , Second Semester, Seminar
  16. 2024, Graduate Education (Master's Program) , First Semester, Research
  17. 2024, Graduate Education (Master's Program) , Second Semester, Research
  18. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar
  19. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar
  20. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Research
  21. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Research
  22. 2024, Graduate Education (Master's Program) , 4Term, General Pharmacology
  23. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Cellular and Molecular Pharmacology
  24. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Cellular and Molecular Pharmacology
  25. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Cellular and Molecular Pharmacology
  26. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Cellular and Molecular Pharmacology

Research Activities

Academic Papers

  1. Overexpression of VIPR2 in mice results in microencephaly with paradoxical increased white matter volume, Exp Neurol, 362, 114339, 2023
    Link to Paper Search Results by DOI
  2. Development of the vasoactive intestinal peptide receptor 2 (VIPR2) antagonist peptide for the treatment of schizophrenia, Nihon Yakurigaku Zasshi, 158(3), 242-245, 2023
    Link to Paper Search Results by DOI
  3. Suppressive effect of black tea polyphenol theaflavins in a mouse model of ovalbumin-induced food allergy, J Nat Med, 77(3), 604-609, 2023
    Link to Paper Search Results by DOI
  4. N-methyl-D-aspartate receptors and glycinergic transmission, respectively, mediate muscle relaxation and immobility of pentobarbital in mice, Neurosci Lett, 802, 137175, 2023
    Link to Paper Search Results by DOI
  5. Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway, Peptides, 161, 170940, 2023
    Link to Paper Search Results by DOI
  6. Roles of the monoaminergic system in the antidepressant effects of ketamine and its metabolites, Neuropharmacology, 223, 2023
    Link to Paper Search Results by DOI
  7. Physiological concentrations of glucocorticoids induce pathological DNA double-strand breaks, Genes Cells, 28(1), 53-67, 2023
    Link to Paper Search Results by DOI
  8. A new method for assessing depressive-like behaviors in female mice, Nihon Yakurigaku Zasshi, 158(1), 35-38, 2023
    Link to Paper Search Results by DOI
  9. Vasoactive intestinal peptide-VIPR2 signaling regulates tumor cell migration, Front Oncol, 12, 2022
    Link to Paper Search Results by DOI
  10. AlphaFold version 2.0 elucidates the binding mechanism between VIPR2 and KS-133, and reveals an S-S bond (Cys(25)-Cys(192)) formation of functional significance for VIPR2, Biochem Biophys Res Commun, 636, 10-16, 2022
    Link to Paper Search Results by DOI
  11. Prenatal exposure to valproic acid causes allodynia associated with spinal microglial activation, Neurochem Int, 160, 2022
    Link to Paper Search Results by DOI
  12. Phospholipase C-related catalytically inactive protein enhances cisplatin-induced apoptotic cell death, Eur J Pharmacol, 933, 2022
    Link to Paper Search Results by DOI
  13. Anti-interleukin-6 receptor antibody improves allodynia and cognitive impairment in mice with neuropathic pain following partial sciatic nerve ligation, Int Immunopharmacol, 112, 2022
    Link to Paper Search Results by DOI
  14. Autism spectrum disorder model mice induced by prenatal exposure to valproic acid exhibit enhanced empathy-like behavior via oxytocinergic signaling, Biol Pharm Bull, 45(8), 1124-1132, 2022
    Link to Paper Search Results by DOI
  15. High-mobility group box 1-mediated hippocampal microglial activation induces cognitive impairment in mice with neuropathic pain, Exp Neurol, 355, 114146, 2022
    Link to Paper Search Results by DOI
  16. Claustrum mediates bidirectional and reversible control of stress-induced anxiety responses, Sci Adv, 8(11), eabi6375, 2022
    Link to Paper Search Results by DOI
  17. Oxytocin ameliorates impaired social behavior in a mouse model of 3q29 deletion syndrome, Mol Brain, 15(1), 26, 2022
    Link to Paper Search Results by DOI
  18. Physicochemical and biochemical evaluation of amorphous solid dispersions of naringenin prepared using hot-melt extrusion, Front Nutr, 9, 850103, 2022
    Link to Paper Search Results by DOI
  19. Examination of dissolution ratio of beta-carotene in water for practical application of beta-carotene amorphous solid dispersion, J Food Sci Technol, 59, 114-122, 2022
    Link to Paper Search Results by DOI
  20. Generation of KS-133 as a novel bicyclic peptide with a potent and selective VIPR2 antagonist activity that counteracts cognitive decline in a mouse model of psychiatric disorders, Front Pharmacol, 12, 751587, 2021
    Link to Paper Search Results by DOI
  21. Multiple alterations in glutamatergic transmission and dopamine D2 receptor splicing in induced pluripotent stem cell-derived neurons from patients with familial schizophrenia, Transl Psychiatry, 11(1), 548, 2021
    Link to Paper Search Results by DOI
  22. Investigation of direct nose-to-brain peptide delivery enhanced by coadministration with penetratin, Pharmaceutics, 13, 1745, 2021
    Link to Paper Search Results by DOI
  23. Intranasal oxytocin administration ameliorates social behavioral deficits in a POGZ WT/Q1038R mouse model of autism spectrum disorder, Mol Brain, 14(1), 56, 2021
    Link to Paper Search Results by DOI
  24. The pivotal role of pituitary adenylate cyclase-activating polypeptide for lactate production and secretion in astrocytes during fear memory, Pharmacol Rep, 73(4), 1109-1121, 2021
    Link to Paper Search Results by DOI
  25. Safety and efficacy of an anti-claudin-5 monoclonal antibody to increase blood-brain barrier permeability for drug delivery to the brain in a non-human primate, J Control Release, 336, 105-111, 2021
    Link to Paper Search Results by DOI
  26. Probing the VIPR2 Microduplication Linkage to Schizophrenia in Animal and Cellular Models, Front Neurosci, 15, 717490, 2021
    Link to Paper Search Results by DOI
  27. Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypes, Nat Commun, 11(1), 859, 2020
    Link to Paper Search Results by DOI
  28. Direct visualization of an antidepressant analog using surface-enhanced Raman scattering in the brain, JCI Insight., 5(6), 133348, 2020
    Link to Paper Search Results by DOI
  29. Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression, OncoImmunology, 9(1), 1734268, 2020
    Link to Paper Search Results by DOI
  30. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression, Pharmacol Biochem Behav, 191, 172876, 2020
    Link to Paper Search Results by DOI
  31. Improved Bioavailability of beta-Carotene by Amorphous Solid Dispersion Technology in Rats, J Nutr Sci Vitaminol, 66(2), 207-210, 2020
    Link to Paper Search Results by DOI
  32. Activation of the VPAC2 Receptor Impairs Axon Outgrowth and Decreases Dendritic Arborization in Mouse Cortical Neurons by a PKA-Dependent Mechanism, Front Neurosci, 14, 521, 2020
    Link to Paper Search Results by DOI
  33. Lipocalin-type prostaglandin D synthase regulates light-induced phase advance of the central circadian rhythm in mice, Commun Biol, 3(1), 557, 2020
    Link to Paper Search Results by DOI
  34. The Role of Genetic and Environmental Factors in Neuropsychiatric Disorders, The Journal of Hiroshima University Dental Society, 52(2), 55-61, 2020
  35. Autism-associated protein kinase D2 regulates embryonic cortical neuron development, Biochem Biophys Res Commun, 519(3), 626-632, 2019
    Link to Paper Search Results by DOI
  36. (R)-Ketamine Induces a Greater Increase in Prefrontal 5-HT Release Than (S)-Ketamine and Ketamine Metabolites via an AMPA Receptor-Independent Mechanism, Int J Neuropsychopharmacol, 22(10), 665-674, 2019
    Link to Paper Search Results by DOI
  37. Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity in a mouse model of 3q29 deletion syndrome, Neuropsychopharmacology, 44(12), 2125-2135, 2019
    Link to Paper Search Results by DOI
  38. Whole-brain block-face serial microscopy tomography at subcellular resolution using FAST, Nat Protoc, 14(5), 1509-1529, 2019
    Link to Paper Search Results by DOI
  39. Pituitary Adenylate Cyclase-Activating Polypeptide Modulates Dendritic Spine Maturation and Morphogenesis via MicroRNA-132 Upregulation, J Neurosci, 39(22), 4208-4220, 2019
    Link to Paper Search Results by DOI
  40. Kamiuntanto increases prefrontal extracellular serotonin levels and ameliorates depression-like behaviors in mice, J Pharmacol Sci, 139(2), 72-76, 2019
    Link to Paper Search Results by DOI
  41. The Robo4-TRAF7 complex suppresses endothelial hyperpermeability in inflammation, J Cell Sci, 132(1), jcs220228, 2019
    Link to Paper Search Results by DOI
  42. mS-11, a mimetic of the mSin3-binding helix in NRSF, ameliorates social interaction deficits in a prenatal valproic acid-induced autism mouse model, Pharmacol Biochem Behav, 176, 1-5, 2019
    Link to Paper Search Results by DOI
  43. LY341495, an mGluR2/3 Antagonist, Regulates the Immunosuppressive Function of Myeloid-Derived Suppressor Cells and Inhibits Melanoma Tumor Growth, Biol Pharm Bull, 41(12), 1866-1869, 2018
    Link to Paper Search Results by DOI
  44. Valproic acid attenuates immunosuppressive function of myeloid-derived suppressor cells, J Pharmacol Sci, 137(4), 359-365, 2018
    Link to Paper Search Results by DOI
  45. Repeated social defeat stress impairs attentional set shifting irrespective of social avoidance and increases female preference associated with heightened anxiety, Sci Rep, 8(1), 10454, 2018
    Link to Paper Search Results by DOI
  46. Beta-Arrestin1 and 2 differentially regulate PACAP-induced PAC1 receptor signaling and trafficking, PLoS ONE, 13(5), e0196946, 2018
    Link to Paper Search Results by DOI
  47. Pathophysiological implication of the VPAC2 receptor in psychiatric disorders, Nihon Yakurigaku Zasshi, 151(6), 249-253, 2018
    Link to Paper Search Results by DOI
  48. Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism, EMBO Rep, 19(3), e44860, 2018
    Link to Paper Search Results by DOI
  49. Impaired extinction of cued fear memory and abnormal dendritic morphology in the prelimbic and infralimbic cortices in VPAC2 receptor (VIPR2)-deficient mice., Neurobiol Learn Mem, 145, 222-231, 2017
    Link to Paper Search Results by DOI
  50. Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism, Horm Behav, 96, 130-136, 2017
    Link to Paper Search Results by DOI
  51. Risperidone and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice, Psychopharmacology, 234(21), 3217-3228, 2017
    Link to Paper Search Results by DOI
  52. Prenatal exposure to valproic acid increases miR-132 levels in the mouse embryonic brain, Mol Autism, 8, 33, 2017
    Link to Paper Search Results by DOI
  53. Environmental enrichment attenuates behavioral abnormalities in valproic acid-exposed autism model mice, Behav Brain Res, 333, 67-73, 2017
    Link to Paper Search Results by DOI
  54. High-Speed and Scalable Whole-Brain Imaging in Rodents and Primates, Neuron, 94(6), 1085-1100, 2017
    Link to Paper Search Results by DOI
  55. Psychopharmacology of combined activation of the serotonin1A and sigma1 receptors., Eur J Pharmacol, 809, 172-177, 2017
    Link to Paper Search Results by DOI
  56. Decreased cohesin in the brain leads to defective synapse development and anxiety-related behavior, J Exp Med, 214(5), 1431-1452, 2017
    Link to Paper Search Results by DOI
  57. Role of Prefrontal Serotonergic and Dopaminergic Systems in Encounter-Induced Hyperactivity in Methamphetamine-Sensitized Mice, Int J Neuropsychopharmacol, 20(5), 410-421, 2017
    Link to Paper Search Results by DOI
  58. Regulation of emotional behaviors by juvenile environmental factors, Nihon Yakurigaku Zasshi, 149(2), 76-78, 2017
    Link to Paper Search Results by DOI
  59. Anti-anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice, Br J Pharmacol, 174(4), 314-327, 2017
    Link to Paper Search Results by DOI
  60. Distribution of Silver Nanoparticles to Breast Milk and Their Biological Effects on Breast-Fed Offspring Mice, ACS Nano, 10(9), 8180-8191, 2016
    Link to Paper Search Results by DOI
  61. Prostaglandin D2 signaling mediated by the CRTH2 receptor is involved in MK-801-induced cognitive dysfunction, Behav Brain Res, 314, 77-86, 2016
    Link to Paper Search Results by DOI
  62. Involvement of GABAA receptors in 5-HT1A and sigma1 receptor synergism on prefrontal dopaminergic transmission under circulating neurosteroid deficiency, Psychopharmacology, 233(17), 3125-3134, 2016
    Link to Paper Search Results by DOI
  63. Prenatal Exposure to Histone Deacetylase Inhibitors Affects Gene Expression of Autism-Related Molecules and Delays Neuronal Maturation, Neurochem Res, 41(10), 2574-2584, 2016
    Link to Paper Search Results by DOI
  64. High-resolution characterization of a PACAP-EGFP transgenic mouse model for mapping PACAP-expressing neurons, J Comp Neurol, 524(18), 3827-3848, 2016
    Link to Paper Search Results by DOI
  65. The novel method female encounter test, Nihon Yakurigaku Zasshi, 147(4), 230-234, 2016
    Link to Paper Search Results by DOI
  66. Improvement by methylphenidate and atomoxetine of social interaction deficits and recognition memory impairment in a mouse model of valproic acid-induced autism, Autism Res, 9(9), 926-939, 2016
    Link to Paper Search Results by DOI
  67. Rivastigmine improves isolation rearing-induced prepulse inhibition deficits via muscarinic acetylcholine receptors in mice, Psychopharmacology, 233(3), 521-528, 2016
    Link to Paper Search Results by DOI
  68. Decreased expression of hippocampal Na⁺/Ca²⁺ exchanger isoform-1 by pentylenetetrazole kindling in mice, Epilepsy Res, 115, 109-112, 2015
    Link to Paper Search Results by DOI
  69. The Female Encounter Test: A Novel Method for Evaluating Reward-Seeking Behavior or Motivation in Mice, Int J Neuropsychopharmacol, 18(11), pyv062, 2015
    Link to Paper Search Results by DOI
  70. Pharmacological profile of encounter-induced hyperactivity in isolation-reared mice, Behav Pharmacol, 26, 681-690, 2015
    Link to Paper Search Results by DOI
  71. p13 overexpression in pancreatic beta-cells ameliorates type 2 diabetes in high-fat-fed mice, Biochem Biophys Res Commun, 461(4), 612-617, 2015
    Link to Paper Search Results by DOI
  72. Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide, Neuroscience, 297, 95-104, 2015
    Link to Paper Search Results by DOI
  73. Reduced prefrontal dopaminergic activity in valproic acid-treated mouse autism model, Behav Brain Res, 289, 39-47, 2015
    Link to Paper Search Results by DOI
  74. PACAP enhances axon outgrowth in cultured hippocampal neurons to a comparable extent as BDNF, PLoS ONE, 10(3), e0120526, 2015
    Link to Paper Search Results by DOI
  75. Role of the 5-HT1A autoreceptor in the enhancement of fluvoxamine-induced increases in prefrontal dopamine release by adrenalectomy/castration in mice, J Pharmacol Sci, 127(2), 232-235, 2015
    Link to Paper Search Results by DOI
  76. Simultaneous neuron- and astrocyte-specific fluorescent marking, Biochem Biophys Res Commun, 459(1), 81-86, 2015
    Link to Paper Search Results by DOI
  77. Shp2 in forebrain neurons regulates synaptic plasticity, locomotion, and memory formation in mice, Mol Cell Biol, 35(9), 1557-1572, 2015
    Link to Paper Search Results by DOI
  78. CRTH2, a prostaglandin D2 receptor, mediates depression-related behavior in mice, Behav Brain Res, 284, 131-137, 2015
    Link to Paper Search Results by DOI
  79. Anxiolytic-like effects of restraint during the dark cycle in adolescent mice, Behav Brain Res, 284, 103-111, 2015
    Link to Paper Search Results by DOI
  80. Reductions in synaptic proteins and selective alteration of prepulse inhibition in male C57BL/6 mice after postnatal administration of a VIP receptor (VIPR2) agonist, Psychopharmacology, 232(12), 2181-2189, 2015
    Link to Paper Search Results by DOI
  81. Identification of the role of bone morphogenetic protein (BMP) and transforming growth factor-beta (TGF-beta) signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells in vitro, J Neurochem, 132(4), 418-428, 2015
    Link to Paper Search Results by DOI
  82. Behavioral characterization of mice overexpressing human dysbindin-1, Mol Brain, 7, 74, 2014
    Link to Paper Search Results by DOI
  83. Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism, Pharmacol Biochem Behav, 126, 43-49, 2014
    Link to Paper Search Results by DOI
  84. An enriched environment ameliorates memory impairments in PACAP-deficient mice, Behav Brain Res, 272, 269-278, 2014
    Link to Paper Search Results by DOI
  85. Neurochemical basis for social encounter-induced hyperactivity in post-weaning isolation-reared mice, Nihon Shinkei Seishin Yakurigaku Zasshi, 34(4), 101-107, 2014
  86. Potential role of serotonin1A receptors in post-weaning social isolation-induced abnormal behaviors in rodents, J Pharmacol Sci, 125(3), 237-241, 2014
    Link to Paper Search Results by DOI
  87. The role of Pak-interacting exchange factor-beta phosphorylation at serines 340 and 583 by PKC gamma in dopamine release, J Neurosci, 34(28), 9268-9280, 2014
    Link to Paper Search Results by DOI
  88. Galantamine promotes adult hippocampal neurogenesis via M₁ muscarinic and alpha7 nicotinic receptors in mice, Int J Neuropsychopharmacol, 17(12), 1957-1968, 2014
    Link to Paper Search Results by DOI
  89. Social crowding in the night-time reduces an anxiety-like behavior and increases social interaction in adolescent mice, Behav Brain Res, 270, 37-46, 2014
    Link to Paper Search Results by DOI
  90. Atomoxetine-induced increases in monoamine release in the prefrontal cortex are similar in spontaneously hypertensive rats and Wistar-Kyoto rats, Neurochem Res, 39(5), 825-832, 2014
    Link to Paper Search Results by DOI
  91. Effects of acute and chronic administration of venlafaxine and desipramine on extracellular monoamine levels in the mouse prefrontal cortex and striatum, Eur J Pharmacol, 729, 86-93, 2014
    Link to Paper Search Results by DOI
  92. Involvement of prefrontal AMPA receptors in encounter stimulation-induced hyperactivity in isolation-reared mice, Int J Neuropsychopharmacol, 17(6), 883-893, 2014
    Link to Paper Search Results by DOI
  93. Isolation rearing reduces mechanical allodynia in a mouse model of chronic inflammatory pain, Pharmacol Biochem Behav, 113, 46-52, 2013
    Link to Paper Search Results by DOI
  94. Synergistic effect of 5-HT1A and sigma1 receptor activation on prefrontal dopaminergic transmission under circulating steroid deficiency, Neuropharmacology, 75, 53-61, 2013
    Link to Paper Search Results by DOI
  95. Methylphenidate and venlafaxine attenuate locomotion in spontaneously hypertensive rats, an animal model of attention-deficit/hyperactivity disorder, through alpha2-adrenoceptor activation, Behav Pharmacol, 24(4), 328-331, 2013
    Link to Paper Search Results by DOI
  96. Effect of overexpression of the brain-specific Na(+)/Ca(2+) exchanger splice variant NCX1.5 on NO cytotoxicity in HEK293 cells., J Pharmacol Sci, 121(4), 351-354, 2013
    Link to Paper Search Results by DOI
  97. The glial sodium-calcium exchanger: a new target for nitric oxide-mediated cellular toxicity, Curr Protein Pept Sci, 14(1), 43-50, 2013
    Link to Paper Search Results by DOI
  98. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants, Neuropharmacology, 66, 40-52, 2013
    Link to Paper Search Results by DOI
  99. Role of social encounter-induced activation of prefrontal serotonergic systems in the abnormal behaviors of isolation-reared mice, Neuropsychopharmacology, 38(8), 1535-1547, 2013
    Link to Paper Search Results by DOI
  100. Effects of serotonin-norepinephrine reuptake inhibitors on locomotion and prefrontal monoamine release in spontaneously hypertensive rats, Eur J Pharmacol, 702(1-3), 250-257, 2013
    Link to Paper Search Results by DOI
  101. Involvement of spinal 5-HT1A receptors in isolation rearing-induced hypoalgesia in mice, Psychopharmacology, 227(2), 251-261, 2013
    Link to Paper Search Results by DOI
  102. The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses psychomotor abnormalities and recognition memory deficits in mice lacking the pituitary adenylate cyclase-activating polypeptide, Behav Pharmacol, 24(1), 74-77, 2013
    Link to Paper Search Results by DOI
  103. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice, Neuropharmacology, 65, 29-38, 2013
    Link to Paper Search Results by DOI
  104. Galantamine increases hippocampal insulin-like growth factor 2 expression via alphs7 nicotinic acetylcholine receptors in mice, Psychopharmacology, 225(3), 543-551, 2013
    Link to Paper Search Results by DOI
  105. Autism-like behaviours with transient histone hyperacetylation in mice treated prenatally with valproic acid, Int J Neuropsychopharmacol, 16(1), 91-103, 2013
    Link to Paper Search Results by DOI
  106. Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with 11C-labeled 20-HETE synthase-specific inhibitor, J Cereb Blood Flow Metab, 32(9), 1737-1746, 2012
    Link to Paper Search Results by DOI
  107. Pharmacological profiles of galantamine: the involvement of muscarinic receptor, Nihon Shinkei Seishin Yakurigaku Zasshi, 32(1), 1-8, 2012
  108. Neuronal nitric oxide synthase inhibition attenuates the development of L-DOPA-induced dyskinesia in hemi-Parkinsonian rats, Eur J Pharmacol, 683(1-3), 166-173, 2012
    Link to Paper Search Results by DOI
  109. Effect of prenatal valproic acid exposure on cortical morphology in female mice, J Pharmacol Sci, 118(4), 543-546, 2012
    Link to Paper Search Results by DOI
  110. The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses isolation rearing-induced abnormal behaviors in mice, J Pharmacol Sci, 118(2), 295-298, 2012
    Link to Paper Search Results by DOI
  111. Lithium attenuates methamphetamine-induced hyperlocomotion and behavioral sensitization via modulation of prefrontal monoamine release, Neuropharmacology, 62(4), 1634-1639, 2012
    Link to Paper Search Results by DOI
  112. Involvement of Sigma-1 Receptors in the Pharmacological Properties of Fluvoxamine, Jap J Stress Sci, 27(1), 104-111, 2012
  113. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease, Neuropharmacology, 61(8), 1441-1451, 2011
    Link to Paper Search Results by DOI
  114. Donepezil, but not galantamine, blocks muscarinic receptor-mediated in vitro and in vivo responses, Synapse, 65(12), 1373-1377, 2011
    Link to Paper Search Results by DOI
  115. Preventive effects of an enriched environment on rodent psychiatric disorder models, J Pharmacol Sci, 117(2), 71-76, 2011
    Link to Paper Search Results by DOI
  116. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine, J Pharmacol Sci, 116(1), 6-17, 2011
    Link to Paper Search Results by DOI
  117. The specific Na(+)/Ca(2+) exchange inhibitor SEA0400 prevents nitric oxide-induced cytotoxicity in SH-SY5Y cells, Neurochem Int, 59(1), 51-58, 2011
    Link to Paper Search Results by DOI
  118. Fluvoxamine enhances prefrontal dopaminergic neurotransmission in adrenalectomized/castrated mice via both 5-HT reuptake inhibition and sigma(1) receptor activation, Psychopharmacology, 217(3), 377-386, 2011
    Link to Paper Search Results by DOI
  119. Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission, Psychopharmacology, 217(3), 443-452, 2011
    Link to Paper Search Results by DOI
  120. Role of endogenous pituitary adenylate cyclase-activating polypeptide in adult hippocampal neurogenesis, Neuroscience, 172, 554-561, 2011
    Link to Paper Search Results by DOI
  121. Involvement of decreased muscarinic receptor function in prepulse inhibition deficits in mice reared in social isolation, Br J Pharmacol, 162(3), 763-772, 2011
    Link to Paper Search Results by DOI
  122. Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice, Neuropharmacology, 60(2-3), 397-404, 2011
    Link to Paper Search Results by DOI
  123. Stress-evoked tyrosine phosphorylation of signal regulatory protein alpha regulates behavioral immobility in the forced swim test, J Neurosci, 30(31), 10472-10483, 2010
    Link to Paper Search Results by DOI
  124. The Na+/Ca2+ exchanger-mediated Ca2+ influx triggers nitric oxide-induced cytotoxicity in cultured astrocytes., Neurochem Int, 57(1), 58-66, 2010
    Link to Paper Search Results by DOI
  125. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice, J Neurochem, 114(1), 259-270, 2010
    Link to Paper Search Results by DOI
  126. Environmental factors during early developmental period influence psychobehavioral abnormalities in adult PACAP-deficient mice, Behav Brain Res, 209(2), 274-280, 2010
    Link to Paper Search Results by DOI
  127. Galantamine improves apomorphine-induced deficits in prepulse inhibition via muscarinic ACh receptors in mice, Br J Pharmacol, 156(1), 173-180, 2009
    Link to Paper Search Results by DOI
  128. Role of prefrontal dopaminergic neurotransmission in glucocorticoid receptor-mediated modulation of methamphetamine-induced hyperactivity, Synapse, 63(1), 7-14, 2009
    Link to Paper Search Results by DOI
  129. Depression and corticosteroid receptors, Nihon Yakurigaku Zasshi, 134(6), 304-308, 2009
    Link to Paper Search Results by DOI
  130. Mitochondrial dysfunction and neuronal apoptosis: new molecular approach to prevent Alzheimer's disease, Nihon Yakurigaku Zasshi, 134(4), 180-183, 2009
    Link to Paper Search Results by DOI
  131. Antidepressant-like effects of the glucocorticoid receptor antagonist RU-43044 are associated with changes in prefrontal dopamine in mouse models of depression, Neuropharmacology, 55(8), 1355-1363, 2008
    Link to Paper Search Results by DOI
  132. A neuroprotective agent, T-817MA (1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl} azetidin-3-ol maleate), prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice, Neuropharmacology, 55(5), 654-660, 2008
    Link to Paper Search Results by DOI
  133. Involvement of Prefrontal Serotonergic Neurons in Methamphetamine-Induced Behavioral Sensitization, Nihon Shinkei Seishin Yakurigaku Zasshi, 28(2), 85-91, 2008
  134. The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice, Eur J Pharmacol, 583(1), 164-169, 2008
    Link to Paper Search Results by DOI
  135. Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice, Psychopharmacology, 196(2), 293-301, 2008
    Link to Paper Search Results by DOI
  136. Neuropsychotoxicity of abused drugs: effects of serotonin receptor ligands on methamphetamine- and cocaine-induced behavioral sensitization in mice, J Pharmacol Sci, 106(1), 15-21, 2008
    Link to Paper Search Results by DOI
  137. Methamphetamine-induced hyperactivity and behavioral sensitization in PACAP deficient mice, Peptides, 28(9), 1674-1679, 2007
    Link to Paper Search Results by DOI
  138. Nitric oxide-induced apoptosis in cultured rat astrocytes: protection by edaravone, a radical scavenger, Glia, 55(13), 1325-1333, 2007
    Link to Paper Search Results by DOI
  139. Ritanserin reverses repeated methamphetamine-induced behavioral and neurochemical sensitization in mice, Synapse, 61(9), 757-763, 2007
    Link to Paper Search Results by DOI
  140. Anxiety-like and exploratory behaviors of isolation-reared mice in the staircase test, J Pharmacol Sci, 104(2), 153-158, 2007
    Link to Paper Search Results by DOI
  141. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum, J Pharmacol Exp Ther, 322(1), 274-281, 2007
    Link to Paper Search Results by DOI
  142. Edaravone, a radical scavenger, inhibits mitochondrial permeability transition pore in rat brain, J Pharmacol Sci, 103(4), 434-437, 2007
    Link to Paper Search Results by DOI
  143. Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholine release in rat prefrontal cortex, Eur J Pharmacol, 559(2-3), 155-160, 2007
    Link to Paper Search Results by DOI
  144. Lack of enhanced effect of antipsychotics combined with fluvoxamine on acetylcholine release in rat prefrontal cortex, J Pharmacol Sci, 102(4), 419-422, 2006
    Link to Paper Search Results by DOI
  145. Role of serotonin type 1A receptors in fluvoxamine-induced inhibition of marble-burying behavior in mice, Behav Pharmacol, 17(7), 637-640, 2006
    Link to Paper Search Results by DOI
  146. Effects of osemozotan, ritanserin and azasetron on cocaine-induced behavioral sensitization in mice, Pharmacol Biochem Behav, 85(1), 198-205, 2006
    Link to Paper Search Results by DOI
  147. Modification of cocaine-induced behavioral and neurochemical effects by serotonin1A receptor agonist/antagonist in mice, Synapse, 60(7), 479-484, 2006
    Link to Paper Search Results by DOI
  148. Expression of prokineticin receptors in mouse cultured astrocytes and involvement in cell proliferation, Brain Res, 1112(1), 65-69, 2006
    Link to Paper Search Results by DOI
  149. Serotonergic inhibition of intense jumping behavior in mice lacking PACAP (Adcyap1-/-), Ann N Y Acad Sci, 1070, 545-549, 2006
    Link to Paper Search Results by DOI
  150. Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice, Neuropharmacology, 51(4), 914-922, 2006
    Link to Paper Search Results by DOI
  151. Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum, Eur J Pharmacol, 542(1-3), 92-99, 2006
    Link to Paper Search Results by DOI
  152. Psychostimulant-induced attenuation of hyperactivity and prepulse inhibition deficits in Adcyap1-deficient mice, J Neurosci, 26(19), 5091-5097, 2006
    Link to Paper Search Results by DOI
  153. T-817MA, a novel neurotrophic agent, improves sodium nitroprusside-induced mitochondrial dysfunction in cortical neurons, Neurochem Int, 48(2), 124-130, 2006
    Link to Paper Search Results by DOI
  154. Effect of zotepine on dopamine, serotonin and noradrenaline release in rat prefrontal cortex, Eur J Pharmacol, 528(1-3), 95-98, 2005
    Link to Paper Search Results by DOI
  155. Antidepressant-like effect of coadministration of sulpiride and fluvoxamine in mice, Eur J Pharmacol, 520(1-3), 86-90, 2005
    Link to Paper Search Results by DOI
  156. SEA0400, a specific inhibitor of the Na+-Ca2+ exchanger, attenuates sodium nitroprusside-induced apoptosis in cultured rat microglia, Br J Pharmacol, 144(5), 669-679, 2005
    Link to Paper Search Results by DOI
  157. Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex, Neuropsychopharmacology, 30(1), 43-51, 2005
    Link to Paper Search Results by DOI
  158. Possible involvement of astrocytes in neuroprotection by the cognitive enhancer T-588, Neurochem Res, 28(12), 1779-1783, 2003
    Link to Paper Search Results by DOI
  159. Regulation by 5-HT1A receptors of the in vivo release of 5-HT and DA in mouse frontal cortex, Neuropharmacology, 45(8), 1050-1056, 2003
    Link to Paper Search Results by DOI
  160. Protective effect of T-588 on toxic damage by serum deprivation and amyloid-beta protein in cultured neurons, J Pharmacol Sci, 92(2), 153-156, 2003
    Link to Paper Search Results by DOI
  161. The 5-HT1A receptor agonist MKC-242 reverses isolation rearing-induced deficits of prepulse inhibition in mice, Psychopharmacology, 170(1), 73-79, 2003
    Link to Paper Search Results by DOI
  162. The 5-HT1A receptor agonist MKC-242 increases the exploratory activity of mice in the elevated plus-maze, Eur J Pharmacol, 458(1-2), 141-144, 2003
    Link to Paper Search Results by DOI
  163. Brain microdialysis of isolation-reared mice under freely-moving conditions, Nihon Yakurigaku Zasshi, 122(2), 135-140, 2003
  164. Modulation by 5-hT2A receptors of aggressive behavior in isolated mice, Jpn J Pharmacol, 89(1), 89-92, 2002
    Link to Paper Search Results by DOI
  165. Selective reduction by isolation rearing of 5-HT1A receptor-mediated dopamine release in vivo in the frontal cortex of mice, J Neurochem, 83(2), 353-359, 2002
    Link to Paper Search Results by DOI
  166. Involvement of benzodiazepine binding sites in an antiaggressive effect by 5-HT(1A) receptor activation in isolated mice, Eur J Pharmacol, 432(2-3), 163-166, 2001
    Link to Paper Search Results by DOI
  167. Functional alteration of brain dopaminergic system in isolated aggressive mice, Nihon Shinkei Seishin Yakurigaku Zasshi, 21(3), 71-76, 2001

Publications such as books

  1. 2021/01, The CELL, Research aimed at elucidating the molecular mechanism for stress-related psychiatric disorders and the development of therapeutic drug through PACAP signaling, 2021, 1, Scholarly Book, Joint work, 日本語, Atsuko Hayata, Yukio Ago, Hitoshi Hashimoto
  2. 2020/06, Medical Science Digest, Research aimed at elucidating the molecular mechanism for stress-related psychiatric disorders and the development of therapeutic drug through PACAP signaling, The New Science Co., Ltd., 2020, 6, Scholarly Book, Joint work, 日本語, Atsuko Hayata, Yukio Ago, Hitoshi Hashimoto
  3. 2016/04, Neuropathology of Drug Addictions and Substance Misuse, Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants, and International Aspects, Methamphetamine-induced hyperlocomotion: a focus on the role of the prefrontal serotonergic system, Academic Press, 2016, Scholarly Book, Joint work, 英語, Ago Y, Takuma K, Matsuda T, 978-0128002124, 1182, 320-328
    Amazon URL
  4. 2016, Pituitary Adenylate Cyclase Activating Polypeptide — PACAP, PACAP modulation of CNS and peripheral inflammation, Springer, 2016, Scholarly Book, Joint work, 英語, Ago Y, Condro MC, Rajbhandari AK, Van C, Jayaram B, May V, Waschek JA, 978-3-319-35133-9, 651-670
  5. 2016, Pituitary Adenylate Cyclase Activating Polypeptide — PACAP, Implications of PACAP signaling in psychiatric disorders, Springer, 2016, Scholarly Book, Joint work, 英語, Hashimoto H, Shintani N, Ago Y, Hayata-Takano A, Nakazawa T, Hashimoto R, Matsuzaki S, Katayama T, Tohyama M, Matsuda T, Baba A, 978-3-319-35133-9, 757-766

Invited Lecture, Oral Presentation, Poster Presentation

  1. VIPR2 copy number variants as a risk factor for schizophrenia, Yukio Ago, Okinawa Institute of Science and Technology Graduate University (OIST) seminar, 2023/02/15, With Invitation, English, Okinawa, Japan
  2. Regulation of cancer migration by VIP−VPAC2 receptor signaling, Yukio Ago, Okinawa Institute of Science and Technology Graduate University (OIST) lecture, 2023/02/15, With Invitation, English, Okinawa, Japan
  3. Activation of the rostral agranular insular cortex is involved in the antidepressant actions of arketamine, Yukio Ago, Rei Yokoyama, Atsushi Kasai, Masato Tanuma, Misuzu Hayashida, Yuto Shimazaki, Momoko Higuchi, Hisato Igarashi, Kaoru Seiriki, Shun Yamaguchi, Takanobu Nakazawa, Kenji Hashimoto, Hitoshi Hashimoto, The 61st Annual Meeting of the American College of Neuropsychopharmacology (ACNP), 2022/12/07, Without Invitation, English, American College of Neuropsychopharmacology, Phoenix, Arizona, USA
  4. Claustrum mediates stress-induced anxiety responses and stress resistance, Hitoshi Hashimoto, Misaki Niu, Masato Tanuma, Kaoru Seiriki, Yukio Ago, Shun Yamaguchi, Atsushi Kasai, The 61st Annual Meeting of the American College of Neuropsychopharmacology (ACNP), 2022/12/07, Without Invitation, English, American College of Neuropsychopharmacology, Phoenix, Arizona, USA
  5. Involvement of the agranular insular cortex in antidepressant actions of arketamine, Rei Yokoyama, Yukio Ago, Atsushi Kasai, Masato Tanuma, Misuzu Hayashida, Yuto Shimazaki, Momoko Higuchi, Hisato Igarashi, Kaoru Seiriki, Shun Yamaguchi, Takanobu Nakazawa, Kenji Hashimoto, Hitoshi Hashimoto, The 96th Annual Meeting of the Japanese Pharmacological Society, 2022/12/03, Without Invitation, English, Japanese Pharmacological Society, Yokohama, Japan
  6. Inhibition of histone deacetylase in utero causes spinal microglial activation and mechanical allodynia in mice, Eiji Imado, Samnang Sun, Tran Ngoc Bao Huynh, Yoki Nakamura, Kazue Nakashima, Norimitsu Morioka, Norikazu Kiguchi, Satoshi Asano, Yukio Ago, The 96th Annual Meeting of the Japanese Pharmacological Society, 2022/12/02, Without Invitation, English, Japanese Pharmacological Society, Yokohama, Japan
  7. A TRPV1 antagonist AMG517 alleviates abnormal pain sensitivity and improves social deficits in the prenatal valproic acid-induced mouse model of autism, Takeru Tahara, Eiji Imado, Haruki Kawase, Momoko Higuchi, Hidekuni Yamakawa, Koichi Ogawa, Yaichiro Kotake, Kazuhiro Takuma, Hitoshi Hashimoto, Satoshi Asano, Yukio Ago, The 96th Annual Meeting of the Japanese Pharmacological Society, 2022/12/02, Without Invitation, English, Japanese Pharmacological Society, Yokohama, Japan
  8. New treatment perspectives in autism spectrum disorder: Role of brain region-specific opioid system balance in ameliorating social impairments, Yukio Ago, The 96th Annual Meeting of the Japanese Pharmacological Society, 2022/11/30, With Invitation, English, Japanese Pharmacological Society, Yokohama, Japan
  9. Phospholipase C like protein PRIP1 PH-domain-containing liposomes enhance apoptotic cell death in cisplatin resistant breast cancer cells, Satoshi Asano, Yukio Ago, Takashi Kanematsu, The 96th Annual Meeting of the Japanese Pharmacological Society, 2022/11/30, Without Invitation, English, Japanese Pharmacological Society, Yokohama, Japan
  10. Intranasal oxytocin administration suppresses social contact-induced neural activity in a POGZ-Q1038R mutant mouse model of autism spectrum disorder, Kohei Kitagawa, Masayuki Baba, Tomoya Takemoto, Masato Tanuma, Misuzu Hayashida, Shun Yamaguchi, Yukio Ago, Kaoru Seiriki, Atsuko Hayata-Takano, Kazuhiro Takuma, Atsushi Kasai, Hitoshi Hashimoto, Takanobu Nakazawa, The 52nd Annual Meeting of the Society for Neuroscience (Neuroscience 2022), 2022/11/15, Without Invitation, English, Society for Neuroscience, San Diego, USA
  11. Agranular insular cortex mediates the antidepressant actions of arketamine, Rei Yokoyama, Yukio Ago, Atsushi Kasai, Masato Tanuma, Misuzu Hayashida, Yuto Shimazaki, Momoko Higuchi, Hisato Igarashi, Kaoru Seiriki, Shun Yamaguchi, Takanobu Nakazawa, Kenji Hashimoto, Hitoshi Hashimoto, The 52nd Annual Meeting of the Society for Neuroscience (Neuroscience 2022), 2022/11/13, Without Invitation, English, Society for Neuroscience, San Diego, USA
  12. KS-133, a novel peptide antagonist targeting VIPR2 for the treatment of schizophrenia, Yukio Ago, Kotaro Sakamoto, Satoshi Asano, VPAC ISBAP 2022 (Joint symposium of the 1st Meeting of the International Society for Bioactive Peptides and the 15th International Symposium on VIP, PACAP and Related Peptides), 2022/11/01, With Invitation, English, International Society for Bioactive Peptides International Symposium on VIP, PACAP and Related Peptides, Osaka, Japan
  13. The VIP/VIPR2 pathway regulates breast cancer cell migration, Satoshi Asano, Misa Yamasaka, Kairi Ozasa, Kotaro Sakamoto, Atsuko Hayata-Takano, Takanobu Nakazawa, Hitoshi Hashimoto, James A. Waschek, Yukio Ago, VPAC ISBAP 2022 (Joint symposium of the 1st Meeting of the International Society for Bioactive Peptides and the 15th International Symposium on VIP, PACAP and Related Peptides), 2022/10/31, Without Invitation, English, International Society for Bioactive Peptides International Symposium on VIP, PACAP and Related Peptides, Osaka, Japan
  14. Neuron-specific overexpression of human VPAC2 receptors in mice causes cognitive dysfunction, Ami Ono, Daichi Koan, Satoshi Asano, Tatsunori Miyaoka, Lu Chen, Mei Yamada, Shinsaku Nakagawa, Atsuko Hayata-Takano, Takanobu Nakazawa, Akihiro Harada, Hitoshi Hashimoto, James A. Waschek, Yukio Ago, VPAC ISBAP 2022 (Joint symposium of the 1st Meeting of the International Society for Bioactive Peptides and the 15th International Symposium on VIP, PACAP and Related Peptides), 2022/10/30, Without Invitation, English, International Society for Bioactive Peptides International Symposium on VIP, PACAP and Related Peptides, Osaka, Japan
  15. Impaired neurodevelopment in iPS cell-derived neural stem cells from psychiatric patients with 7q36.3 microduplication, Kohei Kitagawa, Masayuki Baba, Tomoya Takemoto, Kazuki Nagayasu, Atsushi Kasai, Kazuhiro Takuma, Ryota Hashimoto, Hitoshi Hashimoto, Yukio Ago, Takanobu Nakazawa, VPAC ISBAP 2022 (Joint symposium of the 1st Meeting of the International Society for Bioactive Peptides and the 15th International Symposium on VIP, PACAP and Related Peptides), 2022/10/30, Without Invitation, English, International Society for Bioactive Peptides International Symposium on VIP, PACAP and Related Peptides, Osaka, Japan
  16. The neuropeptide receptor VIPR2 regulates tumor cell migration through PI3K pathway, Satoshi Asano, Yukio Ago, The 64th Annual Meeting of Japanese Association for Oral Biology, 2022/09/19, Without Invitation, Japanese, Japanese Association for Oral Biology, Tokushima, Japan
  17. Prenatal exposure to valproic acid induces proliferation of microglia in the spinal cord and mechanical allodynia in mice, Yukio Ago. Eiji Imado, Sun Samnang, Yoki Nakamura, Kazue Nakashima, Norimitsu Morioka, Kazuhiro Takuma, Norikazu Kiguchi, Satoshi Asano, Neuro2022, 2022/06/30, Without Invitation, English
  18. Pharmacological study of a novel peptide antagonist targeting VIPR2, a class-B GPCR, for the treatment of schizophrenia, Yukio Ago, Kotaro Sakamoto, The 95th Annual Meeting of the Japanese Pharmacological Society, 2022/03/09, With Invitation, Japanese, The Japanese Pharmacological Society, Fukuoka
  19. Functional importance of the oligomer formation of the neuropeptide receptor VIPR2, Satoshi Asano, Kairi Ozasa, Takanobu Nakazawa, James A. Waschek, Yukio Ago, The 95th Annual Meeting of the Japanese Pharmacological Society, 2022/03/09, Without Invitation, Japanese, The Japanese Pharmacological Society, Fukuoka
  20. A neuropeptide VIP induces cell migration by activating the PI3K pathway via VPAC2 receptors, Kairi Ozasa, Satoshi Asano, Misa Yamasaka, Atsuko Hayata, Takanobu Nakazawa, Hitoshi Hashimoto, James A. Waschek, Yukio Ago, The 95th Annual Meeting of the Japanese Pharmacological Society, 2022/03/09, Without Invitation, Japanese, The Japanese Pharmacological Society, Fukuoka
  21. The effect of neutralizing antibody against high-mobility group box 1 on cognitive impairment in mice with neuropathic pain, Natsuki Yoshimoto, Kazue Hisaoka-Nakashima, Kazuto Ohata, Yoki Nakamura, Dengli Wang, Keyue Liu, Hidenori Wake, Yukio Ago, Masahiro Nishibori, Norimitsu Morioka, The 95th Annual Meeting of the Japanese Pharmacological Society, 2022/03/08, Without Invitation, Japanese, The Japanese Pharmacological Society, Fukuoka
  22. Involvement of microglia in mechanical allodynia in a mouse model of neurodevelopmental disorder, Eiji Imado, Sun Samnang, Abrar Abawa, Satoshi Asano, Yoki Nakamura, Kazue Nakashima, Norimitsu Morioka, Kazuhiro Tsuga, Masahiro Irifune, Kazuhiro Takuma, Norikazu Kiguchi, Yukio Ago, The 95th Annual Meeting of the Japanese Pharmacological Society, 2022/03/08, Without Invitation, Japanese, The Japanese Pharmacological Society, Fukuoka
  23. Reduced prefrontal hub function in brain networks associated with social deficits of an ASD model mouse, Atsushi Kasai, Yusuke Iyanaga, Hiroki Ueno, Yuka Nakai, Yuta Hara, Hiroki Miura, Masato Tanuma, Misuzu Hayashida, Rei Yokoyama, Jin Ohkubo, Kaoru Seiriki, Atsuko Hayata-Takano, Shun Yamaguchi, Shiho Kitaoka, Tomoyuki Furuyashiki, Yukio Ago, Takanobu Nakazawa, Kazuhiro Takuma, Hitoshi Hashimoto, The 95th Annual Meeting of the Japanese Pharmacological Society, 2022/03/08, Without Invitation, Japanese, The Japanese Pharmacological Society, Fukuoka
  24. Animal models of depression: A lesson from the pharmacologic sensitivity of antidepressant drugs and candidates, Yukio Ago, The 95th Annual Meeting of the Japanese Pharmacological Society, 2022/03/07, With Invitation, Japanese, The Japanese Pharmacological Society, Fukuoka
  25. A potent and highly selective VPAC2 receptor antagonist peptide KS-133 counteracts cognitive impairment in a mouse model relevant to schizophrenia, Yukio Ago, Lu Chen, Tatsunori Miyaoka, Mei Yamada, Teruaki Masutani, Kenji Ishimoto, Shinsaku Nakagawa, Satoshi Asano, Kotaro Sakamoto, The 60th Annual Meeting of the American College of Neuropsychopharmacology (ACNP), 2021/12/05, Without Invitation, English, American College of Neuropsychopharmacology (ACNP), Puerto Rico
  26. Overexpression of VIPR2 in neurons causes defects in dendritic growth and cognitive impairment, Tatsunori Miyaoka, Lu Chen, Mei Yamada, Daichi Koan, Satoshi Asano, Kenji Ishimoto, Shinsaku Nakagawa, Atsuko Hayata, Takanobu Nakazawa, Akihiro Harada, Hitoshi Hashimoto, James A. Waschek, Yukio Ago, The 7th Congress of the Asian College of Neuropsychopharmacology (AsCNP), 2021/10/22, Without Invitation, English, Asian College of Neuropsychopharmacology (AsCNP), On-line
  27. The neuropeptide VIP-VPAC2 signaling is a novel mechanism of regulating tumor cell migration, Satoshi Asano, Yukio Ago, The 63rd Annual Meeting of Japanese Association for Oral Biology, 2021/10/09, Without Invitation, Japanese
  28. Abnormal pain sensitivity in a prenatal valproic acid-induced mouse model of autism spectrum disorder, Eiji Imado, Sun Samnang, Abrar Rizal Abawa, Satoshi Asano, Kazuhiro Tsuga, Masahiro Irifune, Yukio Ago, The 6th Joint Scientific Meeting in Dentistry, 2021/07/30, Without Invitation, English, On-line
  29. Regulation of tumor cell migration by vasoactive intestinal peptide (VIP)−VPAC2 receptor signaling, Satoshi Asano, Misa Yamasaka, Kairi Ozasa, James A. Waschek, Yukio Ago, The 6th Joint Scientific Meeting in Dentistry, 2021/07/30, Without Invitation, English, On-line
  30. Role of the VPAC2 receptor-mediated signals in cell migration, Misa Yamasaka, Satoshi Asano, Atsuko Hayata, Takanobu Nakazawa, Hitoshi Hashimoto, James Waschek, Yukio Ago, The 141st Annual Meeting of the Pharmaceutical Society of Japan, 2021/03/29, Without Invitation, Japanese, Hiroshima
  31. Neuron-specific VPAC2 receptor overexpression leads to cognitive impairment in mice, Daichi Koan, Eiji Imado, Satoshi Asano, Lu Chen, Tatsunori Miyaoka, Mei Yamada, Kenji Ishimoto, Shinsaku Nakagawa, Atsuko Hayata, Takanobu Nakazawa, Akihiro Harada, Hitoshi Hashimoto, James Waschek, Yukio Ago, The 141st Annual Meeting of the Pharmaceutical Society of Japan, 2021/03/28, Without Invitation, Japanese, Hiroshima
  32. Epigenetic modulation with valproic acid impedes invasion of monocytic myeloid-derived suppressor cells into tumors, Xie Z, Ago Y, Okada N, Tachibana M, The 27th International Symposium on Molecular Cell Biology of Macrophages (MMCB2020), 2020/06/16, Without Invitation, English
  33. PACAP signaling involved in the pathophysiological pathway of psychiatric disorders, Hashimoto H, Hayata-Takano A, Shintani Y, Ago Y, The Akira Arimura Memorial VIP/PACAP and Related Peptides Symposium: 30 years after PACAP Discovery, 2019/11/03, With Invitation, English
  34. ASD-associated de novo POGZ mutations disrupt cortical development, Matsumura K, Seiriki K, Nagase M, Ayabe S, Yamada I, Furuse T, Yamamoto K, Kitagawa K, Baba M, Kasai A, Ago Y, Hayata-Takano A, Shintani N, Iguchi T, Sato M, Yamaguchi S, Tamura M, Wakana S, Yoshiki A, Watabe AM, Okano H, Takuma K, Hashimoto R, Hashimoto H, Nakazawa T, The 49th Annual Meeting of the Society for Neuroscience (Neuroscience 2019), 2019/10/19, Without Invitation, English
  35. In vivo imaging of alkynylated S-citalopram using surface-enhanced Raman scattering, Tanuma M, Kasai A, Bando K, Kotoku N, Higashino K, Ago Y, Kawata S, Fujita K, Hashimoto H, The 49th Annual Meeting of the Society for Neuroscience (Neuroscience 2019), 2019/10/19, Without Invitation, English
  36. Differential behavioral and neurochemical effects of ketamine enantiomers and their metabolites, Yukio Ago, Hitoshi Hashimoto, The 6th Asian College of Neuropsychopharmacology (AsCNP), 2019/10/11, With Invitation, English
  37. Role of the VPAC2 receptor overactivation implicated in schizophrenia susceptibility, Yukio Ago, Oral Neuroscience 2018, 2018/10/07, With Invitation, English, Osaka University, Graduate School of Dentistry, Osaka
  38. Synergistic neurochemical effect of combined sigma1 and 5-HT1A receptor activation under the circulating neuroactive steroid-deficient conditions, Yukio Ago, APSN/JSN 2012, 2012, With Invitation, English, The Asia-Pacific Society for Neurochemistry/The Japanese Society for Neurochemistry, Kobe
  39. Antidepressant-like effect of a metabotropic glutamate 2/3 receptor antagonist, Yukio Ago, The 7th International Meeting on Metabotropic Glutamate Receptors, 2011, With Invitation, English, Taormina, Italy

Awards

  1. 2022/10/23, NPPR Reviewer Award 2022, Editor in Chief, Neuropsychopharmacology Reports
  2. 2022/03/07, Journal of Pharmacological Sciences Excellent Reviewer Award 2021, The Japanese Pharmacological Society
  3. 2019/11/05, Translational Science Award, The 2019 Akira Arimura Memorial VIP/PACAP and Related Peptides International Symposium
  4. 2019/11/05, Poster Award, The 2019 Akira Arimura Memorial VIP/PACAP and Related Peptides International Symposium
  5. 2019/10/11, Neuropsychopharmacology Reports Reviewer Award 2019, The Japanese Society of Neuropsychopharmacology
  6. 2018/03/10, Journal of Pharmacological Sciences Excellent Reviewer Award 2017, The Japanese Pharmacological Society
  7. 2016/07/02, JSNP Excellent Presentation Award for CINP 2016, The Japanese Society of Neuropsychopharmacology
  8. 2016/05/13, Matsuo Award for Encouragement of Young Investigators, The Society for the Study of GPCR
  9. 2014/07/08, Osaka University Presidential Awards for Encouragement, Osaka University
  10. 2014/03/20, The 29th Award for Encouragement of Young Investigators, The Japanese Pharmacological Society
  11. 2014/02/18, Osaka University Presidential Commendation, Osaka University
  12. 2013/10/25, Young Investigator Award, The Japanese Society of Neuropsychopharmacology
  13. 2012/09/30, The Award for Young Investigator, The Japanese Society for Neurochemistry
  14. 2011/09/24, The 2nd Congress of AsCNP Fellowship Award, Asian College of Neuropsychopharmacology (AsCNP)
  15. 2010/01/08, The Young Scientist Award, The Kinki Division of the Pharmaceutical Society of Japan
  16. 2007/07/13, Excellent Presentation Award, Joint Meeting of the 29th Annual Meeting of Japanese Society of Biological Psychiatry and the 37th Annual Meeting of Japanese Society of Neuropsychopharmacology

External Funds

Acceptance Results of Competitive Funds

  1. Grant-in-Aid for Challenging Research (Exploratory), 2021, 2022
  2. Grants-in-Aid for Scientific Research (B), 2020, 2023
  3. Grant-in-Aid for Scientific Research (C), 2016, 2018
  4. Grant-in-Aid for Scientific Research (C), 2013, 2015
  5. Grant-in-Aid for Young Scientists (B), 2011, 2012
  6. Grant-in-Aid for Young Scientists (B), 2009, 2010
  7. Grant-in-Aid for Young Scientists (B), 2006, 2007

Social Activities

History as Committee Members

  1. International Scientific Program Committee, 2021/04, 2022/06, International College of Neuropsychopharmacology (CINP)

History as Peer Reviews of Academic Papers

  1. 2023, Journal of Pharmacological Sciences, Associate Editor
  2. 2023, Neurochemistry International, Editor, Editorial Advisory Board
  3. 2023, Pharmacology, Biochemistry and Behavior, Editorial Advisory Board
  4. 2023, Frontiers in Pharmacology, Review Editor
  5. 2022, Journal of Pharmacological Sciences, Associate Editor
  6. 2022, Neurochemistry International, Editor, Editorial Advisory Board
  7. 2022, Pharmacology, Biochemistry and Behavior, Editorial Advisory Board
  8. 2022, Frontiers in Pharmacology, Review Editor
  9. 2021, Neurochemistry International, Editor, Editorial Advisory Board
  10. 2021, Pharmacology, Biochemistry and Behavior, Editorial Advisory Board
  11. 2021, Journal of Pharmacological Sciences, Editorial Advisory Board
  12. 2021, Frontiers in Pharmacology, Review Editor
  13. 2020, Pharmacology, Biochemistry and Behavior, Editorial Advisory Board
  14. 2020, Journal of Pharmacological Sciences, Editorial Advisory Board
  15. 2020, Frontiers in Pharmacology, Review Editor
  16. 2019, Pharmacology, Biochemistry and Behavior, Editorial Advisory Board
  17. 2019, Journal of Pharmacological Sciences, Editorial Advisory Board
  18. 2019, Journal of Neuroscience Research, Editorial Advisory Board
  19. 2019, Frontiers in Pharmacology, Review Editor
  20. 2018, Journal of Pharmacological Sciences, Editorial Advisory Board
  21. 2018, Journal of Neuroscience Research, Editorial Advisory Board
  22. 2018, Frontiers in Pharmacology, Review Editor
  23. 2017, Journal of Neuroscience Research, Editorial Advisory Board
  24. 2017, Frontiers in Pharmacology, Review Editor
  25. 2016, Journal of Neuroscience Research, Editorial Advisory Board
  26. 2016, Frontiers in Pharmacology, Review Editor
  27. 2015, Frontiers in Pharmacology, Review Editor